Why Investors Should Buy Moderna Stock

Why Investors Should Buy Moderna Stock
InvestorPlace
12/18/2020
Moderna (NASDAQ:
MRNA) has arguably priced in the medium-term proceeds from its vaccine for the novel coronavirus. But Moderna stock does not yet appear to reflect the potential of its other vaccines under development, the promising drugs it can acquire in the future, or its own status as a potential takeover target.
© Provided by InvestorPlace
The Moderna (MRNA) logo surrounded by syringes, pills and disposable face masks.
Of course Moderna’s vaccine, MRNA-1273, recently won emergency-use approval (EUA) from the FDA. Moreover, Moderna’s vaccine generated excellent efficacy and safety data  in its Phase 3 trial, and, along with the vaccine produced by

Related Keywords

Colorado ,United States ,John Torres ,Ascannio Shutterstock , ,Investorplace The Moderna ,Seeking Alpha ,Generate Returns ,Bottom Line ,கொலராடோ ,ஒன்றுபட்டது மாநிலங்களில் ,ஜான் டோரஸ் ,தேடுவது ஆல்பா ,ஜெநரேட் வருமானம் ,கீழே வரி ,